DCM
CLLS

DAFNA Capital Management’s Cellectis CLLS Stock Holding History

DAFNA Capital Management’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-76,404
Closed -$1.97M – 77
2017
Q2 		$1.97M Hold
76,404
– – 1.41% 24
2017
Q1 		$1.83M Buy
+76,404
New +$1.61M 1.55% 23

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

DAFNA Capital Management's CLLS Position: Q3 2017 in Review

DAFNA Capital Management sold out of Cellectis (CLLS) in Q3 2017, closing a stake of 76,404 shares — an estimated $1.97M sold.

DAFNA Capital Management first reported a position in CLLS in Q1 2017 and held it in 2 quarters. The position peaked at $1.97M in Q2 2017. 42 funds tracked by Wall St. Rank hold CLLS as of Q3 2017.

  • DAFNA Capital Management reported no remaining Cellectis position as of Q3 2017 after selling out during the quarter.
  • DAFNA Capital Management sold 76,404 Cellectis shares in Q3 2017, an estimated $1.97M.
  • DAFNA Capital Management first reported a position in Cellectis in Q1 2017 and held it in 2 quarters.
  • DAFNA Capital Management's Cellectis position peaked at $1.97M in Q2 2017.
  • 42 funds tracked by Wall St. Rank held Cellectis as of Q3 2017.

Based on DAFNA Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.